VIVIMEDLAB NSE filing

Vivimed Labs EGM held on 10 Dec 2025

The RealCase readMedium impact Neutral

Vivimed Labs held an Extraordinary General Meeting (EGM) on December 10, 2025, to vote on the resolution for initiating pre-packaged insolvency resolution process.

Why it matters

The EGM addressed a significant resolution regarding the insolvency process, which could have a notable impact on the company and its stakeholders.

The market read

The announcement is factual and relates to the proceedings of an EGM, with no inherent positive or negative sentiment.

* Extraordinary General Meeting (EGM) of Vivimed Labs Limited was held on Wednesday, December 10, 2025, at 3:00 P.M. through Video Conferencing (VC) / Other Audio Visual Means (OAVM). * Dr. Manohar Rao Varalwar, Chairman of the Company, chaired the proceedings. * The meeting commenced at 3:00 P.M and concluded at 3:30 P.M * Remote e-voting commenced on Sunday, December 07, 2025 at 9:00 a.m. (IST) and ended on Tuesday, December 09, 2025 at 05:00 p.m. (IST). * The special resolution for application to initiate pre-packaged insolvency resolution process under the Insolvency and Bankruptcy Code, 2016 was put to vote. * The results of voting will be declared on the company's website and sent to the Stock Exchange along with the Scrutinizer's Report.

Filing to action

What to do with a filing like this

Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under shareholder meetings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.

View original filing